A Phase 3, Multicenter, Open-Label Extension Study Of Oral Ozanimod For Moderately To Severely Active Crohn's Disease
Funded by
GENEVA
Research Start Date
Status
Active
The primary objective of this study is to demonstrate the long-term safety and efficacy of ozanimod for the treatment of subjects with moderate to severely active Crohn's disease (CD).
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.